Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 31 AL 45

The entorhinal cortex atrophy score for diagnostic distinction between phases of the Alzheimer's disease continuum

Montenegro MLV, Kato CFPA, Batista ARE, Sá AS, Oliveira Neto FS, Aragão MFVV, Araujo LC, Barbosa BJAP.

Arq Neuropsiquiatr. 2026 Nov;84(11):1-10. doi: 10.1055/s-0046-1829131. Epub 2026 Oct 23.

Clinical and biological relevance of objectively-defined subtle cognitive decline in Alzheimer's disease: a narrative review of neuroimaging, biomarker, and clinical progression studies

Gonzalez AI, Martinez JE, Giudicessi A, Rowe M, Ku V, Tristão-Pereira C, He B, Malotaux V, Quiroz YT.

J Prev Alzheimers Dis. 2026 Oct;13(8):100604. doi: 10.1016/j.tjpad.2026.100604. Epub 2026 May 19.

Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment

Kuhn E, Kleineidam L, Stark M, Peters O, Hellmann-Regen J, Preis L, Gref D, Priller J, Spruth EJ, Gemenetzi M, Schneider A, Fliessbach K, Wiltfang J, Bartels C, Hansen N, Rostamzadeh A, Düzel E, Glanz W, Incesoy E, Buerger K, Janowitz D, Stöcklein S, Perneczky R, Rauchmann BS, Teipel SJ, Kilimann I, Laske C, Sodenkamp S, Spottke A, Kronmüller M, Roeske S, Brosseron F, Ramirez A, Synofzik M, Schmid MC, Jessen F, Wagner M; Alzheimer’s Disease Neuroimaging Initiative; DELCODE study group.

J Prev Alzheimers Dis. 2026 Oct;13(8):100609. doi: 10.1016/j.tjpad.2026.100609. Epub 2026 May 29.

Blood-based biomarkers and the current landscape of Alzheimer's disease diagnosis: ethical considerations and practical guidance

Naini SM, Mantyh WG, Waldron EJ, Satin DJ, Basso MR, Garland M, McManimen S, Whiteside DM.

J Clin Exp Neuropsychol. 2026 Oct;48(8):769-781. doi: 10.1080/13803395.2026.2681010. Epub 2026 May 30.

A Multimodal Explainable AI Framework for Early Detection of Alzheimer's Disease Using MRI, PET, and Clinical Assessments

Kirthiga N, Suresh Kumar N.

Semin Ultrasound CT MR. 2026 Oct;47(5):314-325. doi: 10.1053/j.sult.2026.06.009. Epub 2026 Jun 9.

The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status

Milà-Alomà M, Hausle I, Petersen KK, Thropp P, Schindler SE, Tosun D; Alzheimer’s Disease Neuroimaging Initiative.

J Prev Alzheimers Dis. 2026 Oct;13(8):100622. doi: 10.1016/j.tjpad.2026.100622. Epub 2026 Jun 17.

Diagnostic accuracy of CSF and plasma pTau-181, pTau-217, and pTau-231 for Alzheimer's disease: a diagnostic meta-analysis

Mohammed HE, Haseeb ME, Nasser M, Hanen G, Abdelkader MS, Yaser H, Yaser S, Samir A, Arafeh Y, Wagdy M, Darwish MK.

Acta Neurol Belg. 2026 Oct;126(5):1649-1670. doi: 10.1007/s13760-026-03107-8. Epub 2026 Jun 26.

Predicting cognitive function in Alzheimer's clinical trials via amyloid β-protein biomarkers

Sui Z, Feng A, Gong Y, Zha S, Lv Y, Zheng Q, Li L, Wang Y.

Br J Clin Pharmacol. 2026 Oct;92(10):3576-3585. doi: 10.1002/bcp.70665. Epub 2026 Jun 28.

Gingipains as macromolecular mediators at the periodontal-brain interface: Mechanistic, diagnostic, and therapeutic evidence in Alzheimer's and Parkinson's diseases

Dhar I, Gupta S, Mishra R, Dadhich A.

Int J Biol Macromol. 2026 Oct;377:153320. doi: 10.1016/j.ijbiomac.2026.153320. Epub 2026 Jul 2.

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis

Blazhenets G, Soleimani-Meigooni DN, Chiotis K, Allen IE, Rabinovici GD, La Joie R; Meta-Centiloid Study Group; Apostolova LG, Asken BM, Bejanin A, Benzinger TLS, Betthauser TJ, Bluma M, Bombois S, Bourgeat P, Bouteloup V, Braskie MN, Brendel M, Brickman AM, Bryant N, Bullich S, Carrillo MC, Casaletto K, Cash DM, Chang CC, Chang HI, Chao Y, Chêne G, Chételat G, Coath W, Collij LE, Colmant L, Corrada MM, Craft S, Dickerson BC, Dubois B, Dufouil C, Fajardo A, Farrar G, Fortea J, Frings L, Frisoni GB, Gardner RC, Garibotto V, Gnörich JS, Gordon BA, Gu Y, Guan Y, Guo T, Hanseeuw BJ, Hansson O, Harrison TM, Huang Q, Huang SH, Iaccarino L, Ishii K, Ishi K, Jagust WJ, Johnson SC, Kato T, Katsumi Y, Kaye J, Koeppe RA, Kolinger GD, Kramer JH, Landau SM, Landeau B, Lao PJ, Lee S, Lleó A, Lopresti BJ, Lowe VJ, Luchsinger JA, Malpetti M, Mao X, March A, Masters CL, Meyer PT, Mezenge F, Mormino EC, Franquesa-Mullerat M, Nakamura A, Nordberg A, O'Brien JT, O'Bryant SE, Pappas I, Peretti DE, Quenon L, Rowe CC, Rowe JB, Rudolph MD, Salvadó G, Schott JM, Schwartz DL, Schwarz CG, Seo SW, Shekari M, Silbert LC, Smith R, Snyder HM, et al.

JAMA. 2026 Oct 6;336(13):1135-1148. doi: 10.1001/jama.2026.13116.

[(18)F]FDG PET outperforms MRI for detecting early tau-related neurodegeneration

Vourkas O, Zhang L, Jimenez-Pérez A, Sánchez-Martín C, Fernández-Álvarez M, Rabano A, Sánchez-Juan P, Silva-Rodríguez J, Grothe MJ; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2026 Oct;53(12):7504-7513. doi: 10.1007/s00259-026-08093-w. Epub 2026 Jul 20.

Omega-3 fatty acids and Alzheimer's disease-related brain biomarkers in older adults enriched for preclinical Alzheimer's disease

Christifano DN, Kelly E, Sands SA, Honea RA, Morris JK, Burns JM, Taylor MK.

Prostaglandins Leukot Essent Fatty Acids. 2026 Oct;210:102762. doi: 10.1016/j.plefa.2026.102762. Epub 2026 Jul 25.

Development and validation of an amyloid PET dementia of the Alzheimer's type (DAT) score

Edema M, Popuri K, Lee H, Wang L, Beg MF; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2026 Oct;113(3):1263-1276. doi: 10.1177/13872877261476273. Epub 2026 Aug 13.

Rapid plaque clearance with anti-amyloid therapy for Alzheimer's disease: in consideration of donanemab treatment duration from real-world cases

Hwang J, Pietras A, Naasan G, Elahi FM, Gandy S.

Neurocase. 2026 Oct;32(5):229-232. doi: 10.1080/13554794.2026.2730462. Epub 2026 Sep 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias